Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06066515 · ClinicalTrials.gov registry record · Phase 3

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

A Phase 3 study, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 3
Development phase
726
Enrollment target

NCT06066515 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 726 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06066515, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 3
Development phase
726 participants
Enrollment target

Study Summary

This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.

Interventions

  • COMBINATION_PRODUCT Placebo
  • COMBINATION_PRODUCT survodutide

Trial Details

FieldValue
Enrollment Target 726 participants
Start Date 2023-11-25
Est. Completion 2026-02-20
Phase Phase 3

Sponsor

Boehringer Ingelheim

515 total trials

What the Registry Record Tells You About NCT06066515

The ClinicalTrials.gov registry entry for NCT06066515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 726 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06066515 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06066515 about?

NCT06066515 is a clinical study titled "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight". This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not...

What is the current status of trial NCT06066515?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 726 participants. The study started on 2023-11-25. Estimated completion is 2026-02-20.

What interventions are being tested in trial NCT06066515?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), survodutide (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06066515?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.